SG Americas Securities’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-73,069
| Closed | -$102K | – | 3344 |
|
|
2026
Q1 | $102K | Sell |
73,069
-100,432
| -58% | -$138K | ﹤0.01% | 2929 |
|
|
2025
Q4 | $279K | Buy |
173,501
+57,108
| +49% | +$120K | ﹤0.01% | 2788 |
|
|
2025
Q3 | $318K | Buy |
+116,393
| New | +$387K | ﹤0.01% | 2446 |
|
|
2025
Q2 | – | Sell |
-89,023
| Closed | -$171K | – | 2896 |
|
|
2025
Q1 | $171K | Sell |
89,023
-27,748
| -24% | -$56.6K | ﹤0.01% | 2642 |
|
|
2024
Q4 | $222K | Buy |
116,771
+44,806
| +62% | +$77.8K | ﹤0.01% | 2056 |
|
|
2024
Q3 | $95K | Buy |
71,965
+38,821
| +117% | +$51.8K | ﹤0.01% | 3092 |
|
|
2024
Q2 | $34K | Buy |
+33,144
| New | +$41K | ﹤0.01% | 2730 |
|
|
2022
Q1 | – | Sell |
-43,176
| Closed | -$98K | – | 2924 |
|
|
2021
Q4 | $98K | Sell |
43,176
-68,084
| -61% | -$186K | ﹤0.01% | 3091 |
|
|
2021
Q3 | $320K | Buy |
111,260
+98,423
| +767% | +$281K | ﹤0.01% | 2880 |
|
|
2021
Q2 | $49K | Sell |
12,837
-18,080
| -58% | -$60.9K | ﹤0.01% | 2740 |
|
|
2021
Q1 | $105K | Buy |
30,917
+12,421
| +67% | +$44.7K | ﹤0.01% | 3054 |
|
|
2020
Q4 | $52K | Sell |
18,496
-214,366
| -92% | -$626K | ﹤0.01% | 3139 |
|
|
2020
Q3 | $584K | Buy |
232,862
+178,717
| +330% | +$1.57M | ﹤0.01% | 1534 |
|
|
2020
Q2 | $735K | Buy |
54,145
+19,275
| +55% | +$199K | 0.01% | 1718 |
|
|
2020
Q1 | $264K | Buy |
34,870
+9,734
| +39% | +$75.7K | ﹤0.01% | 2322 |
|
|
2019
Q4 | $159K | Buy |
25,136
+10,674
| +74% | +$50.7K | ﹤0.01% | 2646 |
|
|
2019
Q3 | $57K | Buy |
+14,462
| New | +$62K | ﹤0.01% | 2799 |
|
|
2019
Q2 | – | Sell |
-26,797
| Closed | -$219K | – | 3046 |
|
|
2019
Q1 | $219K | Sell |
26,797
-52,227
| -66% | -$358K | ﹤0.01% | 2498 |
|
|
2018
Q4 | $437K | Sell |
79,024
-605
| -0.8% | -$4.73K | ﹤0.01% | 1957 |
|
|
2018
Q3 | $703K | Buy |
+79,629
| New | +$712K | 0.01% | 1937 |
|
|
2017
Q4 | – | Sell |
-8,650
| Closed | -$170K | – | 3155 |
|
|
2017
Q3 | $170K | Sell |
8,650
-534
| -6% | -$8.21K | ﹤0.01% | 2718 |
|
|
2017
Q2 | $132K | Buy |
+9,184
| New | +$116K | ﹤0.01% | 2723 |
|
|
2017
Q1 | – | Sell |
-14,852
| Closed | -$155K | – | 3251 |
|
|
2016
Q4 | $155K | Buy |
+14,852
| New | +$128K | ﹤0.01% | 2546 |
|
|
2016
Q2 | – | Sell |
-10,096
| Closed | -$91K | – | 2579 |
|
|
2016
Q1 | $91K | Buy |
+10,096
| New | +$81.9K | ﹤0.01% | 2648 |
|
Other funds holding AKBA
SG Americas Securities's AKBA Position: Q2 2026 in Review
SG Americas Securities sold out of Akebia Therapeutics (AKBA) in Q2 2026, closing a stake of 73,069 shares — an estimated $102K sold.
SG Americas Securities first reported a position in AKBA in Q1 2016 and held it in 24 quarters. The position peaked at $735K in Q2 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.
- SG Americas Securities reported no remaining Akebia Therapeutics position as of Q2 2026 after selling out during the quarter.
- SG Americas Securities sold 73,069 Akebia Therapeutics shares in Q2 2026, an estimated $102K.
- SG Americas Securities first reported a position in Akebia Therapeutics in Q1 2016 and held it in 24 quarters.
- SG Americas Securities's Akebia Therapeutics position peaked at $735K in Q2 2020.
- 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.
Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.